COMMUNIQUÉS West-GlobeNewswire

NTG Nordic Transport Group Annual Report for 2024

05/03/2025 - 19:05

Company announcement no. 2 – 25 05 March 2025 NTG Nordic Transport Group Annual Report for 2024 NTG Nordic Transport Group A/S (“NTG”) has today published the 2024 Annual Report. Selected financial highlights are [...]

AAPA, PA Foundation leading efforts to improve colorectal cancer screening rates

05/03/2025 - 19:15

ALEXANDRIA, Va., March 05, 2025 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to lead an effort aimed at improving screening rates for colorectal cancer, which is the third deadliest [...]

Holland Bloorview leads national precision health initiative for children and youth

05/03/2025 - 19:42

$12 million investment will sequence genes of 10,000 individuals targeted at neurodevelopmental conditions, mental health and brain injuries TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Holland Bloorview Kids [...]

iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America

05/03/2025 - 20:04

NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft ® , a global leader in cloud-based RIS/PACS [...]

Andromeda Surgical Announces Strategic Partnerships with Richard Wolf and Quanta System, Accelerating Global Growth and Clinical Development

05/03/2025 - 20:07

First Surgical Robot Designed for Continuous Software Evolution—Initial Focus on HoLEP, with Expansion into Other Disease States SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Andromeda Surgical , a [...]

Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination

05/03/2025 - 21:20

CARLSBAD, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands today announced the publication of positive clinical trial results in the journal Food [...]

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05/03/2025 - 22:00

WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]

Plus Therapeutics Announces New Employment Inducement Grants

05/03/2025 - 22:01

HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform [...]

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

05/03/2025 - 22:01

Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDA Anaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDA Initial Anaphylm pediatric clinical trial [...]

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

05/03/2025 - 22:01

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T- [...]

WORK Medical Technology Group LTD Announces Implementation of Dual-Class Share Structure Effective March 6, 2025

05/03/2025 - 22:01

Hangzhou, China, March 05, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices, through its subsidiary, Work (Hangzhou) Medical [...]

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

05/03/2025 - 22:01

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when [...]

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

05/03/2025 - 22:05

Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administration [...]

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

05/03/2025 - 22:05

MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]

Enovis to Participate in Upcoming Investor Conferences

05/03/2025 - 22:05

Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following [...]

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

05/03/2025 - 22:05

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

05/03/2025 - 22:05

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, [...]

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

05/03/2025 - 22:05

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical [...]

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

05/03/2025 - 22:05

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin Acceleration of [...]